Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05210634
Other study ID # 710022US1312
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 11, 2022
Est. completion date May 6, 2022

Study information

Verified date May 2022
Source Canopy Growth Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a two-phase, randomized, double-blind, placebo-controlled, within-participant crossover study to assess the safety, tolerability, PK, and PD of five oral doses of CHI-915 versus placebo in healthy adult participants ages 18-55 years.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date May 6, 2022
Est. primary completion date May 6, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Is a healthy adult aged 18-55 years (inclusive) at the time of screening. 2. Has a body mass index between 18 and 30 kg/m2. 3. Is judged by the Investigator to be in generally good health at screening based on the results of a medical history, physical examination, 12-lead ECG, and clinical laboratory test results. Laboratory results outside of the reference range deemed to be acceptable will be documented as not clinically significant at the discretion of the Investigator. 4. For women of childbearing potential, has a negative serum pregnancy test (ß-human chorionic gonadotropin [hCG]) at the Screening Visit and a negative urine pregnancy test at intake to the research facility. 5. Must be adequately informed of the nature and risks of the study and give written informed consent prior to screening. 6. Is, in the Investigator's opinion, reliable, able, and willing to comply with all protocol requirements and procedures (including scheduled visits). Exclusion Criteria: 1. Women who are pregnant, lactating, breastfeeding, or planning a pregnancy. 2. Women of childbearing potential, or men who are sexually active with a woman of childbearing potential, who are unwilling or unable to use an acceptable method of contraception (abstinence or the use of a highly effective method of contraception, including hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, vasectomy, or intrauterine device) from at least 21 days prior to the first dose of study medication until 28 days after the last dose of study medication. Participants with same sex partners or who maintain abstinence do not require contraception. 3. Person has history of diagnosis related to hepatic function and/or significantly impaired hepatic function (alanine aminotransferase [ALT] >3x upper limit of normal [ULN] or total bilirubin [TBL] >2 x ULN) OR the ALT or aspartate aminotransferase (AST) >2 x ULN and TBL >2 x ULN (or international normalized ratio [INR] >1.5). 4. Has a history of epilepsy. 5. Has used tobacco/nicotine-containing products on more than 10 occasions within 30 days of dosing with study IP or during the study. 6. Has used any prescription drugs or herbal supplements (except hormonal contraception) within 30 days prior to receiving the first dose of IP, unless approved by the Investigator and stable for at least 30 days prior to the first dose of IP through the final study visit. 7. Use of any over-the-counter drugs, vitamins, or supplements within 24 hours prior to dosing with the IP. 8. Has or has previously had a positive result for the presence of Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibodies (HCVAb), or human immunodeficiency virus (HIV) antibodies. 9. Has a positive breath, urine, or serum test for ethanol or a positive urine screen for cocaine, THC, barbiturates, amphetamines, methamphetamines, benzodiazepines, methylenedioxymethamphetamine, phencyclidine, methadone, or opiates at the Screening Visit or prior to IP administration. 10. Any clinically significant condition or abnormal finding at the Screening Visit that would, in the opinion of the Investigator, preclude study participation or interfere with evaluation of the IP. 11. Has a history of a known significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to cannabis, including phytocannabinoids and cannabinoid analogues, or excipients utilized within the IP. 12. Has taken grapefruit products and/or Seville oranges within the 7 days prior to dosing with study medication or during the study. 13. Is taking a prohibited medication or supplement including warfarin, clobazam, valproic acid, phenobarbital, mTOR inhibitors, oral tacrolimus, and St. John's Wort within 30 days prior to receiving the first dose of IP or during the study. 14. Has used cannabis, synthetic cannabinoid, or cannabinoid analogues (e.g., dronabinol, nabilone), hemp products, synthetic cannabinoid receptor agonists (e.g., spice, K2), or any cannabidiol (CBD) or THC-containing product (e.g., Sativex, Epidiolex) within 4 weeks of the Screening Visit or during the study and has used cannabis on more than 25 occasions in the last 12 months. 15. Meets criteria for past-year Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)-defined psychiatric disorder, or moderate to severe substance use disorder. 16. Has a lifetime history of psychosis or schizophrenia or a first-degree relative experiencing psychosis or schizophrenia. 17. Endorses current suicidal intent as indexed by endorsement of questions #4 or #5 on the Columbia-Suicide Severity Rating Scale (C-SSRS). 18. Has suspected or confirmed cardiovascular disease. 19. Has participated in any investigational product or device study within 30 days prior to receiving the first dose of IP or is scheduled to participate in another investigational product or device study during the course of this study. 20. Demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
THCv
THCv in MCT oil

Locations

Country Name City State
United States Nucleus Network Saint Paul Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Canopy Growth Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence, type and severity of AEs/SAEs Incidence, type and severity of AEs/SAEs Day 1
Primary Incidence, type and severity of AEs/SAEs Incidence, type and severity of AEs/SAEs Day 8
Primary Incidence, type and severity of AEs/SAEs Incidence, type and severity of AEs/SAEs Day 15
Primary Incidence, type and severity of AEs/SAEs Incidence, type and severity of AEs/SAEs Day 22
Primary Incidence, type and severity of AEs/SAEs Incidence, type and severity of AEs/SAEs Day 29
Primary Incidence, type and severity of AEs/SAEs Incidence, type and severity of AEs/SAEs Day 36
Primary Change in blood pressure Change in systolic and diastolic blood pressure measured in mmHg Day 1
Primary Change in heart rate Change in heart rate measured in beats per minute Day 1
Primary Change in respiratory rate Change in respiratory rate measured in breaths per minute Day 1
Primary Change in body temperature Change in body temperature measured in degrees Celsius Day 1
Primary Change in blood pressure Change in systolic and diastolic blood pressure measured in mmHg Day 8
Primary Change in heart rate Change in heart rate measured in beats per minute Day 8
Primary Change in respiratory rate Change in respiratory rate measured in breaths per minute Day 8
Primary Change in body temperature Change in body temperature measured in degrees Celsius Day 8
Primary Change in blood pressure Change in systolic and diastolic blood pressure measured in mmHg Day 15
Primary Change in respiratory rate Change in respiratory rate measured in breaths per minute Day 15
Primary Change in heart rate Change in heart rate measured in beats per minute Day 15
Primary Change in body temperature Change in body temperature measured in degrees Celsius Day 15
Primary Change in blood pressure Change in systolic and diastolic blood pressure measured in mmHg Day 22
Primary Change in respiratory rate Change in respiratory rate measured in breaths per minute Day 22
Primary Change in heart rate Change in heart rate measured in beats per minute Day 22
Primary Change in body temperature Change in body temperature measured in degrees Celsius Day 22
Primary Change in blood pressure Change in systolic and diastolic blood pressure measured in mmHg Day 29
Primary Change in heart rate Change in heart rate measured in beats per minute Day 29
Primary Change in respiratory rate Change in respiratory rate measured in breaths per minute Day 29
Primary Change in body temperature Change in body temperature measured in degrees Celsius Day 29
Primary Change in blood pressure Change in systolic and diastolic blood pressure measured in mmHg Day 36
Primary Change in heart rate Change in heart rate measured in beats per minute Day 36
Primary Change in respiratory rate Change in respiratory rate measured in breaths per minute Day 36
Primary Change in body temperature Change in body temperature measured in degrees Celsius Day 36
Primary Change in ECG results Change in ECG results. Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant Day 1
Primary Change in ECG results Change in ECG results. Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant Day 8
Primary Change in ECG results Change in ECG results. Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant Day 15
Primary Change in ECG results Change in ECG results. Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant Day 22
Primary Change in ECG results Change in ECG results. Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant Day 29
Primary Change in ECG results Change in ECG results. Results summarized as Normal, Abnormal not clinically significant, and Abnormal clinically significant Day 36
Secondary Maximum effect for the item "energetic" on the DEQ Maximum effect for the item "energetic" on the Drug Effects Questionnaire. Scale from 0-100 where higher scores indicate more "energetic" Day 1
Secondary Maximum effect for the item "energetic" on the DEQ Maximum effect for the item "energetic" on the Drug Effects Questionnaire. Scale from 0-100 where higher scores indicate more "energetic" Day 8
Secondary Maximum effect for the item "energetic" on the DEQ Maximum effect for the item "energetic" on the Drug Effects Questionnaire. Scale from 0-100 where higher scores indicate more "energetic" Day 15
Secondary Maximum effect for the item "energetic" on the DEQ Maximum effect for the item "energetic" on the Drug Effects Questionnaire. Scale from 0-100 where higher scores indicate more "energetic" Day 22
Secondary Maximum effect for the item "energetic" on the DEQ Maximum effect for the item "energetic" on the Drug Effects Questionnaire. Scale from 0-100 where higher scores indicate more "energetic" Day 29
Secondary Maximum effect for the item "energetic" on the DEQ Maximum effect for the item "energetic" on the Drug Effects Questionnaire. Scale from 0-100 where higher scores indicate more "energetic" Day 36
Secondary Sustained attention - maximum total time on the DVT Sustained attention - maximum total time on the DVT Day 1
Secondary Sustained attention - maximum total time on the DVT Sustained attention - maximum total time on the DVT Day 8
Secondary Sustained attention - maximum total time on the DVT Sustained attention - maximum total time on the DVT Day 15
Secondary Sustained attention - maximum total time on the DVT Sustained attention - maximum total time on the DVT Day 22
Secondary Sustained attention - maximum total time on the DVT Sustained attention - maximum total time on the DVT Day 29
Secondary Sustained attention - maximum total time on the DVT Sustained attention - maximum total time on the DVT Day 36
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by maximum observed plasma concentration Day 1
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by maximum observed plasma concentration Day 8
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by maximum observed plasma concentration Day 15
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by maximum observed plasma concentration Day 22
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by maximum observed plasma concentration Day 29
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by maximum observed plasma concentration Day 36
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration Day 1
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration Day 8
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration Day 15
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration Day 22
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration Day 29
Secondary Pharmacokinetic profile of THCv Pharmacokinetic profile of THCv measured by time to maximum observed plasma concentration Day 36
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04677920 - The Healthy Cookie Energy Study: Understanding How Healthy Cookies Affect Mitochondrial Biology N/A
Active, not recruiting NCT03312920 - Investigating Memory Retrieval Improvement in Healthy Subjects N/A
Completed NCT03309072 - Investigating Accelerated Learning and Memory in Healthy Subjects Using a Face Name Memory Task N/A
Completed NCT03289832 - Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin N/A
Enrolling by invitation NCT06133530 - Human Milk Oligosaccharides (HMOs) and Gut Microbiota, Immune System in Antarctica N/A
Completed NCT05141903 - Dietary Supplement With and Without a Probiotic and/or Antibiotic
Completed NCT01689259 - Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults Phase 1
Completed NCT01187875 - Resistant Starch and Satiety Phase 0
Completed NCT03312699 - Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort Phase 1
Completed NCT03319134 - Investigating the Neural Correlates in Memory Retrieval After HD-tDCS N/A
Recruiting NCT04104360 - Galacto-oligosaccharides and Intestinal Activity N/A
Completed NCT03228693 - Gene Expression and Biomarker Profiling of Keloid Skin N/A
Active, not recruiting NCT04146532 - Aspirin Effects on Emotional Reactions Early Phase 1
Completed NCT04206293 - A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers N/A
Recruiting NCT06011018 - Comparison of Effects of Mirror Therapy Combined With Neuromuscular Electrical Stimulation or Binaural Beats Stimulation on Cortical Excitability, Heart Rate Variability and Lower Limb Motor Function in Patients With Stroke N/A
Completed NCT05093205 - STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS Phase 1
Completed NCT04596709 - Investigation of Blood Glucose and Insulin Response After Intake of Vitalose N/A
Completed NCT04272450 - Respiratory Muscle Strength in Different Age Groups
Completed NCT02044679 - Evaluation of Spot Urine as a Biomarker of Fluid Intake in Real Life Conditions N/A
Completed NCT01402973 - Pilot Study of a Dietary Intervention Based Upon Advanced Glycation End Products N/A